Previous close | 6.20 |
Open | N/A |
Bid | 9.90 |
Ask | 13.20 |
Strike | 75.00 |
Expiry date | 2024-12-20 |
Day's range | 6.20 - 6.20 |
Contract range | N/A |
Volume | |
Open interest | 2 |
Despite flat year-over-year revenue and supply chain hurdles, PBH achieves significant deleveraging and projects optimistic fiscal '25 outlook.
Revenue of $277.0 Million in Q4 and $1,125.4 Million in Fiscal 2024Solid Consumption Trends in Q4 Offset by Near-Term Supply Chain ConstraintsAchieved Leverage Ratio of 2.8x at Year-End, Below Long-Term TargetBoard of Directors Authorize New $300 Million Share Repurchase ProgramInitial Full-Year Fiscal 2025 Organic Revenue Growth and EPS Outlook of Approximately 1% and $4.40 to $4.46, respectively TARRYTOWN, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) toda
Cresco Labs Inc. (CRLBF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.